Use of Antidepressants and Risk of Incident Stroke: A Systematic Review and Meta-Analysis.


Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2019
Historique:
received: 26 03 2019
accepted: 30 04 2019
pubmed: 20 6 2019
medline: 9 6 2020
entrez: 20 6 2019
Statut: ppublish

Résumé

Both depression and use of antidepressants have been reported to be risk factors for stroke, but results from the literature are still not conclusive regarding the risk attributable to antidepressants rather than to the underlying disease. To estimate the risk of incident stroke associated with use of antidepressants, a meta-analysis was performed. PubMed, Medline, Cochrane, ProQuest, Scopus, and bibliographies of articles were searched up to September 2018. The final meta-analysis included 31 observational studies. STROBE statement-checklist and GRADE guidelines were used for quality assessment. The random-effects meta-analysis on the association between use of any antidepressant and risk of any stroke resulted in meta-risk ratio (RR) of 1.41 (95% CI 1.13-1.69, I2 = 93, 7%). The pooled estimate for selective serotonin reuptake inhibitors (SSRIs) resulted in a meta-RR of 1.41 (95% CI 1.13-1.69, I2 = 94, 5%) and for tricyclic antidepressants (TCAs) of 1.08 (95% CI 0.93-1.22, I2 = 0%). SSRI users displayed a higher risk of ischemic (1.57, 95% CI 1.06-2.09, I2 = 96.4%) than hemorrhagic stroke (1.34, 95% CI 1.15-1.53, I2 = 72.9%). Meta-RRs were lower for TCA, although with smaller heterogeneity (ischemic 1.22, 95% CI 0.97-1.46; I2 = 0%; hemorrhagic: 1.00, 95% CI 0.83-1.18, I2 = 0%). Restricting to studies on depressed individuals, both SSRI and TCA remained associated with an increased risk of any stroke type (meta-RR for SSRI: 1.27, 95% CI 1.11-1.43, I2 = 76.6%; meta-RR for TCA: 1.21 (95% CI 1.02-1.40, I2 = 47, 3%). Despite the high heterogeneity, these results demonstrate that even after adjusting for depression, use of antidepressants retains an independent increased risk of stroke.

Sections du résumé

BACKGROUND
Both depression and use of antidepressants have been reported to be risk factors for stroke, but results from the literature are still not conclusive regarding the risk attributable to antidepressants rather than to the underlying disease.
OBJECTIVE
To estimate the risk of incident stroke associated with use of antidepressants, a meta-analysis was performed.
METHODS
PubMed, Medline, Cochrane, ProQuest, Scopus, and bibliographies of articles were searched up to September 2018. The final meta-analysis included 31 observational studies. STROBE statement-checklist and GRADE guidelines were used for quality assessment.
RESULTS
The random-effects meta-analysis on the association between use of any antidepressant and risk of any stroke resulted in meta-risk ratio (RR) of 1.41 (95% CI 1.13-1.69, I2 = 93, 7%). The pooled estimate for selective serotonin reuptake inhibitors (SSRIs) resulted in a meta-RR of 1.41 (95% CI 1.13-1.69, I2 = 94, 5%) and for tricyclic antidepressants (TCAs) of 1.08 (95% CI 0.93-1.22, I2 = 0%). SSRI users displayed a higher risk of ischemic (1.57, 95% CI 1.06-2.09, I2 = 96.4%) than hemorrhagic stroke (1.34, 95% CI 1.15-1.53, I2 = 72.9%). Meta-RRs were lower for TCA, although with smaller heterogeneity (ischemic 1.22, 95% CI 0.97-1.46; I2 = 0%; hemorrhagic: 1.00, 95% CI 0.83-1.18, I2 = 0%). Restricting to studies on depressed individuals, both SSRI and TCA remained associated with an increased risk of any stroke type (meta-RR for SSRI: 1.27, 95% CI 1.11-1.43, I2 = 76.6%; meta-RR for TCA: 1.21 (95% CI 1.02-1.40, I2 = 47, 3%).
CONCLUSIONS
Despite the high heterogeneity, these results demonstrate that even after adjusting for depression, use of antidepressants retains an independent increased risk of stroke.

Identifiants

pubmed: 31216542
pii: 000500686
doi: 10.1159/000500686
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-151

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Slavica Trajkova (S)

Department of Medical Sciences, University of Turin, Turin, Italy.

Angelo d'Errico (A)

Unit of Epidemiology, Regional Health Service ASLTO3, Grugliasco, Italy, angelo.derrico@epi.piemonte.it.

Riccardo Soffietti (R)

Department of Neuro-Oncology, University of Turin, Turin, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital, University of Turin and Centre for Cancer Prevention (CPO), Turin, Italy.

Fulvio Ricceri (F)

Unit of Epidemiology, Regional Health Service ASLTO3, Grugliasco, Italy.
Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH